logo

Potential Blockbuster Drugs

Hemlibra
Hemlibra

Developed by Roche’s Genentech, Hemlibra was approved by the FDA last November to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A who have developed antibodies called Factor VIII (FVIII) inhibitors. It is the first non-blood product approved for this condition.

Hemlibra, a first-in-class therapeutic, whose active ingredient is emicizumab, is given weekly via injection under the skin (subcutaneous).

The drug was approved in the European Union in February of this year.

Hemlibra, which is designated an Orphan drug, and Breakthrough therapy, is estimated to bring in sales of $496 million in 2018, $1.457 billion in 2019, and $4.002 billion in 2022.

Competitors:

Sanofi’s Eloctate (Sales of $ 724.5 million in 2017)
Shire plc’s Advate and Adynovate (Sales of $2.4 billion in 2017)

Reference: Clarivate Analytics

Recent development:

On March 26, 2018, Genentech announced that since 2016, five adults with hemophilia A with inhibitors taking Hemlibra have passed away.

In each of these cases, the assessment of the treating physician or investigator was that the cause of death was unrelated to Hemlibra, says Genentech.

Share